Baird analyst Jack Allen downgraded Vor Biopharma, Inc. (NASDAQ: VOR) from Outperform to Neutral with a price target of $0.25 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE